Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
Conus
Sébastien
S
Straumann
Alex
A
Simon
Hans-Uwe
HU
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines / Q000096:biosynthesis; D004797:Enzyme-Linked Immunosorbent Assay; D004802:Eosinophilia / Q000097:blood / Q000188:drug therapy*; D004804:Eosinophils / Q000187:drug effects*; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000097:blood*; D008297:Male; D008875:Middle Aged; D053649:Receptors, Interleukin-5 / Q000097:blood / Q000187:drug effects*; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D015848:Interleukin-5; D053649:Receptors, Interleukin-5; C434107:mepolizumab